Smith & Nephew (SNN) Cash from Financing Activities (2009 - 2024)
Smith & Nephew (SNN) posted quarterly Cash from Financing Activities of $372.0 million for Q4 2024, up 532.56% year-on-year from $58.8 million in Q1 2024, and up 532.56% on a QoQ basis from -$86.0 million in Q4 2023.
Smith & Nephew (SNN) Cash from Financing Activities (2009 - 2024) Analysis & Trends
Smith & Nephew (SNN) has reported Cash from Financing Activities for 16 consecutive years, with $372.0 million the latest figure, recorded in Q4 2024.
- Quarterly Cash from Financing Activities rose 532.56% year-over-year to $372.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$720.0 million (up 6.13% YoY) and the FY2025 annual result came in at -$955.0 million, down 1010.47% from the prior year.
- Cash from Financing Activities grew to $372.0 million in Q4 2024 per SNN's latest filing, from -$86.0 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for SNN reached as high as $372.0 million in Q4 2024 and fell as low as -$704.0 million in Q4 2022.
- A 5-year average of -$79.0 million and a median of -$86.0 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities sank 192.92% — and 2024, when it surged 532.56%.
- Year by year, Cash from Financing Activities stood at $325.0 million in 2020, then plunged by 192.92% to -$302.0 million in 2021, then slumped by 133.11% to -$704.0 million in 2022, then surged by 87.78% to -$86.0 million in 2023, then jumped by 532.56% to $372.0 million in 2024.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $372.0 million, -$86.0 million, and -$704.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Steris | 20.59 Bn | 20.16 Bn | 697.10 Mn | -97.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 372.00 Mn |
| Dec 31, 2024 | 372.00 Mn |
| Dec 31, 2023 | -86.00 Mn |
| Dec 31, 2023 | -86.00 Mn |
| Dec 31, 2022 | -704.00 Mn |
| Dec 31, 2022 | -704.00 Mn |
| Dec 31, 2021 | -302.00 Mn |
| Dec 31, 2021 | -302.00 Mn |
| Dec 31, 2020 | 325.00 Mn |
| Dec 31, 2020 | 325.00 Mn |
| Dec 31, 2019 | 303.00 Mn |
| Dec 31, 2019 | 303.00 Mn |
| Dec 31, 2018 | 553.00 Mn |
| Dec 31, 2018 | 553.00 Mn |
| Dec 31, 2017 | -434.00 Mn |
| Dec 31, 2017 | -434.00 Mn |
| Dec 31, 2016 | -529.00 Mn |
| Dec 31, 2016 | -529.00 Mn |
| Dec 31, 2015 | -558.00 Mn |
| Dec 31, 2015 | -558.00 Mn |